Recent

% | $
Quotes you view appear here for quick access.

Concert Pharmaceuticals, Inc. Message Board

  • beepeeess beepeeess Jul 31, 2014 12:25 PM Flag

    CTP-730 instead of CTP-221

    I think the reason they went with CTP-730 first instead of CTP-221 is because Revlimid patents are still active and have a long way to go before they expire, so there's no reason to make Revlimid better right now. If the patents expire and generic's take over, the they can use CTP-221 to make Revlimid better so patients would choose Revlimid over generics. They would actually need CTP-730 to make Otezla better right now because it can't be a blockbuster drug unless it works better. Otherwise, they might use CTP-730 for the lupus drug they're working on, but I'm not sure how I could make sense of that without knowing about competition or how effective their lupus drug is looking so far.

 
CNCE
14.87-0.11(-0.73%)Jul 2 4:00 PMEDT